BioCryst Pharmaceuticals (BCRX) to Release Earnings on Thursday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $151.32 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $7.26 on Thursday. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31. The stock has a market capitalization of $1.53 billion, a P/E ratio of -145.20 and a beta of 0.83. The business has a 50 day simple moving average of $7.10 and a 200-day simple moving average of $7.42.

Wall Street Analyst Weigh In

A number of research firms have commented on BCRX. Barclays reduced their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $17.00 price objective for the company. Zacks Research downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. HC Wainwright increased their target price on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.64.

Insider Activity at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the sale, the insider owned 398,751 shares in the company, valued at approximately $3,050,445.15. This represents a 5.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 183,453 shares of company stock valued at $1,330,965 in the last quarter. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BCRX. Focus Partners Wealth purchased a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth about $77,000. Mercer Global Advisors Inc. ADV acquired a new position in BioCryst Pharmaceuticals during the third quarter valued at approximately $81,000. Elevation Point Wealth Partners LLC purchased a new stake in BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. Cetera Investment Advisers grew its stake in BioCryst Pharmaceuticals by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares during the period. Finally, Quantessence Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $103,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.